Mumbai Angels, now part of 360 ONE, recently expanded its portfolio with a new investment in Vgenomics India. The biotechnology and healthcare startup successfully concluded its seed investment round, led by Mumbai Angels and O2 Angel Network.
This round saw participation from notable angel investors, including Rohit Chanana and Sabine Kapasi.
The company aims to utilize the investment to develop diagnostic solutions and expand its operations in collaboration with neonatologists, gynaecologists, paediatricians, and clinical geneticists.
This financial injection validates their innovative approach and expedites the development and deployment of solutions, targeting the extensive population of 175 million children worldwide affected by rare diseases.
Vgenomics utilizes advanced next-generation sequencing technologies to develop diagnostic and therapeutic solutions for rare pediatric diseases. These conditions, typically arising at birth due to DNA alterations, are the focus of the company’s efforts. By harnessing the power of genomics and artificial intelligence, Vgenomics is introducing innovative solutions to address the needs of over 175 million children grappling with rare diseases worldwide.
Nandini Mansinghka, CEO of Mumbai Angels, shared her thoughts. “Vgenomics’ groundbreaking approach to harnessing next-generation, AI -powered sequencing technologies to address rare diseases is commendable. We believe this investment not only validates their innovative strategy but also propels the journey towards impacting the lives of millions of children affected by rare diseases worldwide.”
